Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Merger or Acquisition (January 2025)
14 slides from Telix Pharmaceuticals's merger presentation, Jan 13, 2025
Slide 1: Acquisition of Next-generation Therapeutic Assets and Novel Biologics Technology Platform
For personal use only Acquisition of Next-generation Therapeutic Assets and Novel Biologics Technology Platform Telix Pharmaceuticals NASDAQ: TLX | ASX: TLX January 2025
Slide 2: Disclaimer
Disclaimer This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our we
Slide 3: Transaction to acquire novel biologics platform and assets
Transaction to acquire novel biologics platform and assets Platform, pipeline, and people from ImaginAb Inc. For personal use only Transaction provides 1. Platform: a proprietary technology platform to generate unique theranostic Telix with multiple (therapeutic + diagnostic) engineered antibodies a
Slide 4: Deal summary
Deal summary Structure: Asset Purchase Agreement with concurrent Technology License Agreement providing additional exclusive and non-exclusive rights to specific patents and know-how retained by ImaginAb. For personal use only Assets Deal summary1 Platform Technology; ongoing Designated Programs; Di
Slide 5: Engineered antibody targeting agents offer best of both worlds
Engineered antibody targeting agents offer best of both worlds Bridging the gap between small molecules and antibodies ‘Antibody fragments’ For personal use only Small Nanobody scFv Diabody Minibody scFv-Fc IgG△CH2 IgG have a molecular molecule/ peptide weight between full- length antibodies and sma
Slide 6: A platform technology ideal for radiopharmaceuticals
A platform technology ideal for radiopharmaceuticals Proprietary technology to develop protein-based therapeutic agents For personal use only Advantage vs. antibodies Advantage vs. small molecules Favorable in vivo targeting characteristics1 60 • Faster tumor uptake • High affinity and targeting sel
Slide 7: New pipeline of therapeutic assets
New pipeline of therapeutic assets Lead compounds validate the utility of the technology platform For personal use only • The acquisition adds a pipeline of therapeutic compounds addressing commercially Program Lead IND3 enabling Clinical Target/Indication Discovery selection studies studies valuabl
Slide 8: New high-value targets: Integrin αvβ6 and DLL3
New high-value targets: Integrin αvβ6 and DLL3 Opportunity to leverage novel theranostic mechanism of action against high value targets For personal use only Integrin αvβ6 (IAB56) DLL3 (IAB57) • Highly expressed across range of cancers with high • Expressed in 85% of SCLC5 unmet need including – 23k
Slide 9: Integrin αvβ6 targeting: Preclinical summary (IAB56)
Integrin αvβ6 targeting: Preclinical summary (IAB56)1 Favorable dosimetry and efficacy For personal use only • Tumor targeting demonstrated in multiple relevant tumor xenograft Preclinical efficacy in multiple models pancreatic cancer models • Efficacy studies highly reproducible, demonstrating sign
Slide 10: DLL3 targeting: Preclinical summary (IAB57)
DLL3 targeting: Preclinical summary (IAB57) 1 Demonstrated efficacy in an unmet clinical need For personal use only • Tumor targeting demonstrated in multiple SCLC Preclinical efficacy in lung cancer model xenograft models SHP-77 model Vehicle • 2500 IAB57 shows excellent manufacturability propertie
Slide 11: Clinical proof of concept
Clinical proof of concept Demonstrates highly specific targeting of cancer with favorable pharmacokinetics1 99mTc-MDP 18F-FDG 89Zr-IAB2M A Serum clearance B Tumor uptake For personal use only 35 16 IAB2M Bone 30 14 IAB2M Soft IgG Bone Serum retention (%ID/L) 12 25 IgG Soft SUV LB M MAX 10 20 8 15 6
Slide 12: Discovery platform, people and lab to bolster R&D capability
Discovery platform, people and lab to bolster R&D capability A faster way to develop candidates across a range of cancer indications For personal use only Rapid “concept to clinical” model • Research and Development laboratory and team provides Telix with ability to identify, characterize and valida
Slide 13: Transaction summary
Transaction summary Reinforcing leadership position in theranostics For personal use only Platform Pipeline People Proprietary technology to generate Opportunity to leverage theranostic New capabilities complement engineered antibody targeting agents MoA1 against high-value targets existing infrastr
Slide 14: Contact details
Contact details: For personal use only Kyahn Williamson SVP Investor Relations and Corporate Communication kyahn.williamson@telixpharma.com
Telix Pharmaceuticals — Merger or Acquisition (January 2025) on 6ix